Use of erythropoietin

A technology of erythropoietin and erythrocytosis, which is applied in the application field of erythropoietin, and can solve problems such as the mobilization and differentiation of endothelial progenitor cells that have not been fully understood

Inactive Publication Date: 2008-01-09
EPOPLUS GMBH & CO KG
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the basic mechanism of mobilization and differenti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of erythropoietin
  • Use of erythropoietin
  • Use of erythropoietin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] Effect of EPO on Patients with Renal Anemia

[0118] The role of EPO in patients with renal anemia (Hb < 10.5 g / dl) was investigated. Wherein, the renal anemia is an inevitable result of the late stage of renal disease (the final stage of renal failure, creatinine clearance <35ml / min). According to the average dose of 5000IU per week, 11 patients were treated with rhEPO (recombinant human erythropoietin) by intravenous injection or subcutaneous injection for at least 8 weeks. Endothelial progenitor cells in the patient's blood were studied within 20 weeks after erythropoietin treatment, during which time, 0, 2, 4, 6 and 8 weeks later, by flow cytometry The number and differentiation state of endothelial progenitor cells were analyzed by counting method and culture analysis method.

[0119] Circulating peripheral blood stem cells (CPBSCs) include a small population of cells that express both CD34 and CD45 antigens. On the basis of the ISHAGE guidelines (Sutherland et ...

Embodiment 2

[0127] Improved wound healing through systemic use of rhEPO

[0128] FVB / N- mice were anesthetized by inhalation of isoflurane (Isoflorane). Remove the hair on the two hind legs with a depilatory solution and disinfect with 70% alcohol. Then, a sterile 4mm disposable biopsy drill was used to create skin wounds on the right side of these mice, and the opposite side was used as a control. A one-time antibiotic treatment was performed with penicillin G (20000 units / kg) after the operation. The recombinant human erythropoietin mimetic Aranesp (0.1 μg / kg body weight) was injected subcutaneously once a week throughout the experimental study period. Treatment begins seven days before the biopsy is removed. As shown in Figure 5, the results showed that the use of EPO accelerated the wound healing process quite significantly.

Embodiment 3

[0130] Prevention of the development of chronic renal failure by erythropoietin therapy

[0131] Eight week old Spraque-Dawley rats were anesthetized with ketamine (120 mg / kg) and xylazine (10 mg / kg). Right kidneys from these mice were removed on day 0 and immediately fixed in formalin for histological studies. The segmental arteries supplying blood to the upper and lower poles of the left kidney were ligated. This leads to renal infarction in the corresponding renal area, while only the middle third of the renal area remains functional. Once a week, these mice were injected subcutaneously with the erythropoietin analog Aranesp at a dose of 0.1 μg / kg body weight, or NaCl as a control group.

[0132] Figure 7 shows the Kaplan-Mayer survival curves for the two experimental groups. Mice treated with Aranesp had significantly improved survival compared to saline-treated control mice.

[0133] Figures 12-15 show that after treatment with erythropoietin, the kidney tissue did no...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the use of erythropoietin for stimulation of the physiological mobilisation, proliferation and differentiation of endothelial precursor cells, for stimulation of vasculogenesis, for the treatment of diseases related to a dysfunction of endothelial precursor cells and for the production of pharmaceutical compositions for the treatment of such diseases and pharmaceutical compositions comprising erythropoietin and other agents suitable for stimulation of endothelial precursor cells.

Description

[0001] This application is a divisional application of the invention patent application whose filing date is July 25, 2003, application number is 03822116.0 (international application number is PCT / EP03 / 08229), and the title of the invention is "Application of Erythropoietin". technical field [0002] The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells; for stimulating angiogenesis; for treating diseases related to endothelial progenitor cell dysfunction; and for producing Pharmaceutical compositions for the treatment of such diseases, and the manufacture of pharmaceutical compositions comprising erythropoietin and other suitable active ingredients capable of stimulating endothelial progenitor cells. Background technique [0003] Vascular endothelium is the layer of cells that lines the inner walls of blood vessels. The endothelium separates the blood from...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/18A61K9/08A61K9/10A61K9/107A61K9/14A61K9/20A61P17/02A61K31/366A61K31/40A61K38/18A61K38/19A61P9/00
CPCA61K38/1866A61K38/1891A61K38/193A61K38/1816A61P11/00A61P13/12A61P15/00A61P17/00A61P17/02A61P29/00A61P3/00A61P3/10A61P35/00A61P3/06A61P43/00A61P9/00A61P9/04A61P9/08A61P9/10A61P9/12A61P9/14A61K2300/00A61K38/18A61K38/17
Inventor 费迪南德·赫尔曼·巴尔曼赫尔曼·哈勒尔
Owner EPOPLUS GMBH & CO KG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap